Merck & Co Inc (LTS:0QAH)
$ 131.3 0 (0%) Market Cap: 260.35 Bil Enterprise Value: 283.89 Bil PE Ratio: 21.58 PB Ratio: 5.86 GF Score: 81/100

Merck & Co Inc at Morgan Stanley Global Healthcare Conference Transcript

Sep 12, 2022 / 06:15PM GMT
Release Date Price: $86.65
Terence C. Flynn
Morgan Stanley, Research Division - Equity Analyst

Okay. Great. Thanks for joining us, everybody. I'm Terence Flynn, the pharma analyst -- U.S. pharma analyst here at Morgan Stanley. We're very pleased to have Merck with us today.

For important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com\researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales representative.

Joining us today from the company, we have Rob Davis, CEO; and Dean Li, Head of R&D. Thank you, gentlemen, for joining us today. Really great to be back in person, and great to have you here today.

Robert M. Davis
Merck & Co., Inc. - President, CEO & Director

Great. Thank you for having us. It's good to be back in person.

Questions & Answers

Terence C. Flynn
Morgan Stanley, Research Division - Equity Analyst

For sure. Maybe, Rob, obviously, newly recently appointed CEO, maybe just help us think

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot